Contact Phenotype-first longevity therapeutics
SYDRA discovers small molecules through whole-organism lifespan biology, then advances the strongest phenotypes toward human targets, mechanisms and disease medicines.
01 / PIPELINE
AI-selected, phenotype-proven programs and a new generative cohort move through one evidence-gated path. Only experimental lifespan HITs graduate into therapeutic programs.
Phenotype-selected
small-molecule program
Healthy aged C57BL/6 mice began treatment at 22 months.
Phenotype-selected
small-molecule program
Healthy aged C57BL/6 mice began treatment at 22 months.
02 / THE PARADIGM
Most drug discovery begins with a target and asks whether a molecule works. SYDRA begins with a lifespan phenotype, then discovers why it works and where it can become a medicine.
SYDRA · HIT-TO-TARGET
Start with an organism-level result. Decode the biology that made it work.
03 / EVIDENCE
In early 2023, SYDRA completed its first million-scale AI-to-organism longevity discovery campaign.
Demonstrated
AI predictions become meaningful only when they survive contact with living biology. Our C. elegans platform identifies molecules with measurable lifespan-extending activity and prioritizes the strongest phenotypes for further development.
Exploratory pilot · n=25–27 per condition · SY23H p = 0.0733 · SY23F p = 0.2945
Pilot signal
Encouraging remaining-lifespan trends emerged after treatment began in naturally aged mice. Confirmatory development is planned.
Initiation underway
Human-cell target and mechanism-of-action program initiation is underway for the lead programs.
04 / TECHNOLOGY
SYDRA separates the model that generates novel chemistry from the discriminator that ranks geroprotective potential, then refines prioritized structures for synthesis.
A machine-learning method based on robust statistics identifies geroprotector-enriched neighborhoods in molecular representation space and derives molecular seeds.
Our proprietary chemical foundation SLM completes those seeds into novel, syntactically valid and chemically plausible structures.
At the heart of both discovery engines is Gero-ANN, SYDRA’s proprietary artificial neural network for ranking both generated and existing molecules by predicted geroprotective potential. Generated structures first pass through RDKit chemical filters before entering Gero-ANN; existing molecules enter it directly.
Ranked structures enter a scientist-guided design loop. Computational chemistry helps us explore analogues and prioritize designs that balance drug-likeness, chemical stability, synthetic feasibility and structural liability risk before synthesis.
Their next decisive test will not be another simulation. It will be biology.
THE SYDRA LOOP
A molecule enters SYDRA as a prediction. A living organism decides whether it matters. Human biology reveals how it can become a medicine.
05 / COMPANY
A Swiss biotechnology company integrating aging biology, experimental lifespan science, and proprietary machine learning.
Focused from day one on AI-discovered molecules and prospective lifespan testing.
Building an IP estate around phenotype-first discovery and therapeutic programs.
Based in Schlieren, Zürich, with an international scientific execution network.
06 / TEAM
A compact, interdisciplinary team spanning drug discovery, machine learning, bioinformatics and structural biology.
ADVISORY BOARD
Pharmacology & Pharmaceutical Medicine
Former Director, Licensing & New Business Development
Global partnering · due diligence · licensingLinkedInNEWS / UPDATES
The latest company, platform and conference updates from SYDRA.
SYDRA has built an integrated pipeline that turns discriminative intelligence into generative discovery.
Read article
SYDRA joins SPRIND’s portfolio and outlines how the support can accelerate its geroprotector discovery loop.
Read article
SYDRA announced its sponsorship of ARDD 2025 in Copenhagen, the conference on aging research and drug discovery.
Read articlePARTNERS / SUPPORTERS
Organizations supporting SYDRA across company building, compute, chemistry, research services and breakthrough innovation.
CONTACT
Whether you are investing, sponsoring research, exploring a partnership, covering our work or pursuing a scientific collaboration, tell us where you see a fit.
